The impact of comorbidity on Health-Related Quality of Life among cancer survivors: Analyses of data from the PROFILES registry

Journal of Cancer Survivorship

Volumn 7, Issue 4, 2013, Pages 602-613

  Vissers, P A J ^a,b   Thong, M S Y ^a,b   Pouwer, F ^a   Zanders, M M J ^b   Coebergh, J W W ^b,c   van de Poll Franse, L V ^a,b  

^a TILBURG UNIVERSITY   (Netherlands)

^b The Netherlands   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cancer; Comorbidity; Elderly; Health related quality of life; Population based

Indexed keywords

ADULT; AGED; ARTICLE; COLORECTAL TUMOR; COMORBIDITY; FEMALE; HEALTH STATUS; HUMAN; MALE; MIDDLE AGED; NETHERLANDS; NONHODGKIN LYMPHOMA; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REGISTER; STATISTICS; SURVIVOR; THYROID TUMOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; COMORBIDITY; FEMALE; HEALTH STATUS; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NETHERLANDS; QUALITY OF LIFE; REGISTRIES; SURVIVORS; THYROID NEOPLASMS;

EID: 84888290112     PISSN: 19322259     EISSN: 19322267     Source Type: Journal    
DOI: 10.1007/s11764-013-0299-1     Document Type: Article

References (43)

1. WHO. Active ageing: a policy framework. Geneva: World Health Organization; 2002.
2. Coleman MP, Gatta G, Verdecchia A, et al. EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Ann Oncol. 2003;14: v128-49.
3. Janssen-Heijnen MLG, Houterman S, Lemmens VEPP, et al. Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. Crit Rev Oncol Hematol. 2005;55: 231-40.
4. Kaplan RM. Quality of life: an outcomes perspective. Arch Phys Med Rehabil. 2002;83: s44-50.
5. Gijsen R, Hoeymans N, Schellevis FG, et al. Causes and consequences of comorbidity: a review. J Clin Epidemiol. 2001;54: 661-74.
6. Baumeister H, Balke K, Härter M. Psychiatric and somatic comorbidities are negatively associated with quality of life in physically ill patients. J Clin Epidemiol. 2005;58: 1090-100.
7. El-Deiry MW, Futran ND, McDowell JA, et al. Influences and predictors of long-term quality of life in head and neck cancer survivors. Arch Otolaryngol Head Neck Surg. 2009;135: 380-4.
8. Terrell JE, Ronis DL, Fowler KE, et al. Clinical predictors of quality of life in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2004;130: 401-8.
9. Wahlgren T, Levitt S, Kowalski J, et al. Use of the Charlson combined comorbidity index to predict postradiotherapy quality of life for prostate cancer patients. Int J Radiat Oncol Biol Phys. 2011;81: 997-1004.
10. Grønberg BH, Sundstrøm S, Kaasa S, et al. Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy. Eur J Cancer. 2010;46: 2225-34.
11. Thong MSY, Mols F, Lemmens VEPP, et al. Impact of chemotherapy on health status and symptom burden of colon cancer survivors: a population-based study. Eur J Cancer. 2011;47: 1798-807.
12. Thong MSY, Mols F, Lemmens VEPP, et al. Impact of preoperative radiotherapy on general and disease-specific health status of rectal cancer survivors: a population-based study. Int J Radiat Oncol Biol Phys. 2011;81: e49-58.
13. Parker PA, Baile WF, Moor C, Cohen L. Psychosocial and demographic predictors of quality of life in a large sample of cancer patients. Psychooncology. 2003;12: 183-93.
14. Lehto U-S, Ojanen M, Kellokumpu-Lehtinen P. Predictors of quality of life in newly diagnosed melanoma and breast cancer patients. Ann Oncol. 2005;16: 805-16.
15. Sangha O, Stucki G, Liang MH, et al. The self-administered comorbidity questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Care Res. 2003;49: 156-63.
16. Arndt V, Stegmaier C, Ziegler H, Brenner H. A population-based study of the impact of specific symptoms on quality of life in women with breast cancer 1 year after diagnosis. Cancer. 2006;107: 2496-503.
17. Carreca I, Balducci L, Extermann M. Cancer in the older person. Cancer Treat Rev. 2005;31: 380-402.
18. van de Poll-Franse LV, Horevoorts N, Eenbergen MV et al. The Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship registry: scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts. Eur J Cancer. 2011;47: 2188-94.
19. Coebergh JWW, Janssen-Heijnen MLG, Louwman WJ, Voogd AC. Cancer incidence and survival in the south of the Netherlands, 1955-1999 & incidence in the north of Belgium, 1996-1998 [CD-ROM]. Eindhoven: Comprehensive Cancer Centre South (IKZ); 2001.
20. Mols F, Denollet J, Kaptein AA, et al. The association between type D personality and illness perceptions in colorectal cancer survivors: a study from the population-based PROFILES registry. J Psychosom Res. 2012;73: 232-9.
21. Mols F, Thong MSY, van de Poll-Franse LV, et al. Type D (distressed) personality is associated with poor quality of life and mental health among 3080 cancer survivors. J Affect Disord. 2012;136: 26-34.
22. Husson O, Haak HR, Buffart LM, et al. Health-related quality of life and disease specific symptoms in long-term thyroid cancer survivors: a study from the population-based PROFILES registry. Acta Oncol. 2013;52: 249-58.
23. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85: 365-76.
24. Hofman M, Ryan JL, Figueroa-Moseley CD, et al. Cancer-related fatigue: the scale of the problem. Oncologist. 2007;12: 4-10.
25. Green CR, Hart-Johnson T, Loeffler DR. Cancer-related chronic pain. Cancer. 2011;117: 1994-2003.
26. Oerlemans S, Mols F, Issa DE, et al. A high level of fatigue among (long-term) non-Hodgkin lymphoma survivors: results from the longitudinal population-based PROFILES registry in the south of the Netherlands. Haematologica. 2013;98(3): 479-86. doi: 10. 3324/haematol. 2012. 064907.
27. Fayers PM, Aaronson NK, Bjordal K, Sullivan M. EORTC QLQ-C30 scoring manual. Brussels, Belgium. 1995;1: 1-49.
28. Ludwig H, van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004;40: 2293-306.
29. Kristjansson S, Wyller T. Introduction. In: Schrijvers D, Aapro M, Zakotnik B et al. (eds): ESMO handbook of cancer in the senior patient, 1st Edition. Switzerland: Informa; 2010.
30. Husson O, Haak HR, Mols F, et al. Development of a disease-specific health-related quality of life questionnaire (THYCA-QoL) for thyroid cancer survivors. Acta Oncol. 2013;52(2): 447-54. doi: 10. 3109/0284186X. 2012. 718445.
31. Østhus A, Aarstad AH, Olofsson J, Aarstad H. Comorbidity is an independent predictor of health-related quality of life in a longitudinal cohort of head and neck cancer patients. Eur Arch Otorhinolaryngol. 2013;270: 1721-8.
32. Kroenke C, Kwan M, Neugut A et al. Social networks, social support mechanisms, and quality of life after breast cancer diagnosis. Breast Cancer Res. Treat. 2013;1-13.
33. Sammarco A. Perceived social support, uncertainty, and quality of life of younger breast cancer survivors. Cancer Nurs. 2001;24: 212-9.
34. Cohen HJ, Lan L, Archer L, Kornblith AB. Impact of age, comorbidity and symptoms on physical function in long-term breast cancer survivors (CALGB 70803). J Geriatr Onco. 2012;3: 82-9.
35. Jensen RE, Arora NK, Bellizzi KM, et al. Health-related quality of life among survivors of aggressive non-Hodgkin lymphoma. Cancer. 2013;119(3): 672-80. doi: 10. 1002/cncr. 27781.
36. Oerlemans S, Mols F, Nijziel M, et al. The impact of treatment, socio-demographic and clinical characteristics on health-related quality of life among Hodgkin's and non-Hodgkin's lymphoma survivors: a systematic review. Ann Hematol. 2011;90: 993-1004.
37. Baumeister H, Kriston L, Bengel J, Härter M. High agreement of self-report and physician-diagnosed somatic conditions yields limited bias in examining mental-physical comorbidity. J Clin Epidemiol. 2010;63: 558-65.
38. Powell H, Lim LLY, Heller RF. Accuracy of administrative data to assess comorbidity in patients with heart disease: an Australian perspective. J Clin Epidemiol. 2001;54: 687-93.
39. Chen RC, Royce TJ, Extermann M, Reeve BB. Impact of age and comorbidity on treatment and outcomes in elderly cancer patients. Semin Radiat Oncol. 2012;22: 265-71.
40. Hancock SL, Cox RS, McDougall IR. Thyroid diseases after treatment of Hodgkin's disease. N Engl J Med. 1991;325: 599-605.
41. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol. 2006;24: 1633-42.
42. Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008;26: 1231-8.
43. Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005;23: 7811-9.